Sorafenib and thyroid cancer (Q38118647)

29 August 2017

Sorafenib and thyroid cancer. (English)

1 reference

29 August 2017

1

Poupak Fallahi

1 reference

29 August 2017

8

Alessandro Antonelli

1 reference

29 August 2017

Silvia Martina Ferrari

2

object named as

Silvia Martina Ferrari

1 reference

29 August 2017

Francesca Santini

3

1 reference

29 August 2017

Alda Corrado

4

1 reference

29 August 2017

Gabriele Materazzi

5

1 reference

29 August 2017

Salvatore Ulisse

6

1 reference

29 August 2017

Paolo Miccoli

7

1 reference

29 August 2017

1 December 2013

1 reference

29 August 2017

1 reference

29 August 2017

27

1 reference

29 August 2017

6

1 reference

29 August 2017

615-628

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-013-0049-y

29 August 2017

0 references

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Management of the patient with progressive radioiodine non-responsive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Dedifferentiated thyroid cancer: a therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Molecular genetics and diagnosis of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

BRAF mutation in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

21 January 2018

Medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

New targeted molecular therapies for dedifferentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Sorafenib in metastatic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Kinase inhibitors for refractory thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0049-Y

10.1007/S40259-013-0049-Y

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference